Although the number of reports on mitomycin C (MMC) pharmacokinetics is increasing, data on possible relations between clinical parameters and pharmacokinetics are usually lacking. The present report concerns the results of a detailed study on this subject in 35 patients receiving MMC, either as a single agent or as a part of combination chemotherapy. MMC concentrations were determined by HPLC.
Introduction
Although mitomycin C (MMC) was isolated in 1958 [14] , extensive pharmacokinetic data have been reported only in the past few years because of earlier problems with insensitive microbiologic assays [3] . Detailed pharmacokinetic data on MMC in man only recently became available [1, 5, 8, 9, 12] MMC combined with one or more of the following drugs: doxorubicin, vincristine, bleomycin, cisplatin, 5-fluorouraeil and hydroxyurea evaporated to dryness under a nitrogen stream, and the residue dissolved in 100 ~tl methanol. Aliquots of 10 gl were injected into the chromatograph, using a Bondapack C~8 reversed phase column and UV detection at 365 nm. The detection limit was I ng/ml sample. The internal standard used was porfiromycin, structurally related to MMC. Methods for pharmacokinetic data analysis have been published by den Hartigh et al. [5] . The investigated clinical data included a complete physical examination, body temperature, heart rate, blood pressure, urine output, values of hemoglobin, white blood cell and platelet count, serum sodium, potassium, creatinin, alkaline phosphatase, 7-glutamyl transferase (7-GT), serum lactate dehydrogenase, albumin, and urinalysis including pH, protein and glucose excretion, and the time and nature of administration of any comedication.
The mean and median values, standard deviation, and standard errors of the pharmacokinetic parameters were calculated for separate dose levels in single agent treatment and combination chemotherapy. Relationships between the obtained pharmacokinetic parameters, the duration of infusion, and the administered dose were analyzed. For individual patients with one or more phanuacokinetic parameters falling beyond the limits of mean _+ 2 SD, we searched for possible relationships with the available clinical data.
This was also done in case of a deviation of the pharmacokinetic curve. The relationship between the pharmacokinetic data and the clinical data was plotted graphically.
Our next approach was to relate pharmacokinetic parameters with the occurrence and degree of clinical toxicity (WHO criteria), which was limited to myelosuppression.
Finally, in patients in whom we performed two or more pharmacokinetic studies, we related the consecutive curves obtained in each patient to the clinical data.
Results

Pharmacokinetic data
The pharmacokinetic data obtained were as follows 
Relation with clinical parameters
Values outside the range mean +_ 2 S D for one or more o f the pharmacokinetic parameters were found on 6 occasions in 6 patients. Physical and laboratory data as investigated did not indicate a reason for the observed a b n o r m a l pharmacokinetic values. In cholestatic patients pharmacokinetics appeared not to be different ( Fig. 2 ) from noncholestatic patients. In 16 patients urinary p H was measured. N o influence o f urinary p H on pharmacokinetic values was encountered. In 26 patients adequate follow-up data on bone m a r r o w toxicity were available. Bone m a r r o w toxicity occurred m u c h more frequently after combination chemotherapy. We did not find any relation between A U C and bone m a r r o w toxicity. 
Interaction with comedication
The deviations that were present in 6 pharmacokinetic curves in 6 different patients could not be explained by data on comedication in 5 o f them. In the 6th patient we performed 7 consecutive pharmacokinetic studies.
In the 1st course he received 10 m g / m z M M C because o f prostatic cancer; during the other courses the dose was 12 m g / m 2. During all cycles comedication consisted o f furosemide, isosorbide dinitrate, and digitalis, all given orally. The pharmacokinetics obtained are depicted in Fig. 3 . They show uniform results in 6 out o f the 7 studies. The only deviating pharmacokinetic data were obtained from the 2nd cycle (b), while the only difference appearing from the clinical charts for this cycle when compared to the others, was the ad- 
Consecutive pharmaeokinetics
Apart from the patient reported above, 2 pharmacokinetic studies per patient were performed in 5 other patients; 4 of these patients received single agent MMC, 1 received combination chemotherapy. The intraindividual findings in these 5 patients were consistent (Fig. 4) . No effect of any clinical condition was observed on the pharmacokinetics in these patients.
Discussion
In this study on 35 patients, we did not find correlations between pharmacokinetics of MMC and clinical parameters. We did confirm the previously reported linear pharmacokinetics of the drug. We also found that cholestasis did not influence the pharmacokinetic behavior of MMC, which confirms previous observations of van Hazel et al. [8] . Although the concentration of MMC in the bile is much higher than in plasma, in rats as well as in man [5, 10] , biliary excretion appears not to be an important pathway of elimination in animals [10] . The present and van Hazel's previous observations in man indicate that metabolism of MMC, occurring at the microsomal level, is not inhibited by cholestasis. It has been suggested that MMC pharmacokinetics are influenced by enterohepatic recycling of the drug [11, 13] . Whether both biliary flow and enterohepatic recycling of MMC play a role in its elimination is not known.
We confirmed previous data [8] that pharmacokinetics of MMC are independent of renal function. In one patient we could not exclude an effect of furosemide on MMC pharmacokinetics. For this reason we initiated a study to investigate this potential effect, the results of which will be reported separately. Another observation was that urinary pH did not influence the elimination of MMC, at least within pH ranges of 5-7. This indicates that the in vitro changes of detectability of MMC at different pHs [7] are not reflected in norreal pH fluctuations in the in vivo situation.
In previous studies using the HPLC assay it has been reported that the pharmacokinetic data on MMC showed wide variations [5, 8] . However, the results obtained in the patient in whom we performed 7 pharmacokinetic studies, as well as the results in 5 patients studied twice, indicated that if clinical data remain stable during treatment, and even if renal function changes, the pharmacokinetics of MMC do not change. If these findings are confirmed in a larger number of patients, they support the advantage of the HPLC assay for MMC pharmacokinetic studies. But still the mechanisms of interindividual variations in those pharmacokinetics have to be elucidated, as they appear not to be dependent on the assay used, or on the clinical variables studied. Preliminary data indicated a protein binding of MMC of 22%__+3% in plasma from 6 healthy volunteers [6] . It seems unlikely that this small range in protein binding can account for the observed interindividual differences in pharmacokinetics. Myelosuppression was infrequent in our patient group and mainly occurred in patients receiving combination chemotherapy. The often delayed bone marrow toxicity of MMC is known to be directly related to cumulative dose and to be rare below a cumulative dose of 50 mg in patients who have not been pretreated [2] , while the mean cumulative dose in the patients we studied was only 20 mg/m z. The majority of them had not been pretreated with other cytotoxic drugs. This probably explains the absence of any relationship between pharmacokinetics and the occurrence and degree of bone marrow toxicity, while the observed toxicity may have been caused by concomitantly administered cytostatics.
